Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning
The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
Drugs that modulate serotonin (5-HT) synaptic concentrations impact neurogenesis and hippocampal (HPC)-dependent learning. The primary objective is to determine the extent to which psilocybin (PSOP) modulates neurogenesis and thereby affects acquisition and extinction of HPC-dependent trace fear conditioning. PSOP, the 5-HT2A agonist 25I-NBMeO and the 5-HT2A/C antagonist ketanserin were administered via an acute intraperitoneal injection to mice. Trace fear conditioning was measured as the amount of time spent immobile in the presence of the conditioned stimulus (CS, auditory tone), trace (silent interval) and post-trace interval over 10 trials. Extinction was determined by the number of trials required to resume mobility during CS, trace and post-trace when the shock was not delivered. Neurogenesis was determined by unbiased counts of cells in the dentate gyrus of the HPC birth-dated with BrdU co-expressing a neuronal marker. Mice treated with a range of doses of PSOP acquired a robust conditioned fear response. Mice injected with low doses of PSOP extinguished cued fear conditioning significantly more rapidly than high-dose PSOP or saline-treated mice. Injection of PSOP, 25I-NBMeO or ketanserin resulted in significant dose-dependent decreases in number of newborn neurons in hippocampus. At the low doses of PSOP that enhanced extinction, neurogenesis was not decreased, but rather tended toward an increase. Extinction of "fear conditioning" may be mediated by actions of the d…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This may explain why they have demonstrated efficacy in many preclinical rodent behavioral tests involving PFC circuitry including the forced swim test and fear extinction learning (151, 194–197).”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [196]
In the citing paper
“At a biological level, psilocybin induced a dose-dependent effect on neurogenesis, with a low dose increasing, and a high dose decreasing neurogenesis (62).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [62]
In the citing paper
“Psilocybin-treated mice exhibited increased extinction compared to saline-treated controls for all doses, indicating a quicker learning response to fear (62).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [62]
In the citing paper
“Mice (n = 6) that were administered a single, low dose of psilocybin (0.1 mg/kg, i.p) showed a non-significant increase in proliferation of hippocampal progenitor cells 14 days later.”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [62]
In the citing paper
“Behavioral effects of psilocybin demonstrated a dose-independent stimulation of fear extinction”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [62]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Running increases cell proliferation and neurogenesis in the adult mouse dentate gyrus
van Praag, H., Kempermann, G., & Gage, F. H. (1999) · Nature Neuroscience · doi:10.1038/6368 · Cited by 3,880
Autoradiographic and histological evidence of postnatal hippocampal neurogenesis in rats
Altman, J., & Das, G. D. (1965) · Journal of Comparative Neurology · doi:10.1002/cne.901240303 · Cited by 3,592 · cited 1×
“Neurogenesis occurs throughout the life span in the adult brain, the subventricular zone (SVZ) and the subgranular zone (SGZ) in the DG (Altman 1962, 1969; Altman and Das 1965).”
BackgroundA review of central 5-HT receptors and their function
Barnes, N. M., & Sharp, T. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00010-6 · Cited by 3,161
Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus
Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-24-09104.2000 · Cited by 3,111
Functional neurogenesis in the adult hippocampus
van Praag, H., Schinder, A. F., Christie, B. R., Toni, N., Palmer, T. D., & Gage, F. H. (2002) · Nature · doi:10.1038/4151030a · Cited by 2,853
Modality-Specific Retrograde Amnesia of Fear
Kim, J. J., & Fanselow, M. S. (1992) · Science · doi:10.1126/science.1585183 · Cited by 2,483
Learning enhances adult neurogenesis in the hippocampal formation
Gould, E., Beylin, A., Tanapat, P., Reeves, A., & Shors, T. J. (1999) · Nature Neuroscience · doi:10.1038/6365 · Cited by 2,157 · cited 1×
“Evidence suggests that performance on HPC-dependent learning tasks is influenced by neurogenesis in the DG of the HPC (Van et al. 2002; Gould et al. 1999a, b; Nilsson et al. 1999; Shors et al. 2001, 2002).”
BackgroundNibuya, M., Morinobu, S., & Duman, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-11-07539.1995 · Cited by 2,109 · cited 1×
“Chronic administration of 5-HT agonists (including SSRIs) upregulates BDNF mRNA expression in the HPC (Nibuya et al. 1995, 1996).”
BackgroundNeurogenesis in the adult is involved in the formation of trace memories
Shors, T. J., Miesegaes, G., Beylin, A., Zhao, M., Rydel, T., & Gould, E. (2001) · Nature · doi:10.1038/35066584 · Cited by 2,023
The Emotional Brain, Fear, and the Amygdala
LeDoux, J. (2003) · Cellular and Molecular Neurobiology · doi:10.1023/a:1025048802629 · Cited by 1,818 · cited 1×
“the dentate gyrus (DG), hilus, cornu ammonis (CA) 1 and CA3 and are colocalized on GABAergic neurons, pyramidal and granular cells (Luttgen et al. 2004; Morilak et al. 1993, 1994; Pompeiano et al. 1994; Shen and Andrade 1998; Cornea-Hebert et al. 1999).”
Background
Cited by
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
“Catlow et al. (2013) investigated the role of psilocybin on hippocampal neurogenesis and trace fear conditioning in rats.”
BackgroundPsychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
“, 2018) and fear extinction learning (Cameron et al., 2018; Catlow et al., 2013; Young et al., 2015), paradigms for which ketamine has also been shown to be effective (Autry et al.”
BackgroundSerotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
“Serotonin 2A receptor activation has also been associated with neurogenesis (Catlow et al., 2013; Cavus and Duman, 2003; Frankel and Cunningham, 2002; Gewirtz et al., 2002; Jones et al., 2009; Meller et al., 2002; Niitsu et al., 1995; Vaidya et al., 1997), particularly in the cortex (Gewirtz et al.”
BackgroundBogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O’Donnell, K., Owens, L. T., Podrebarac, S., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.2096 · Cited by 711
Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders
Vollenweider, F. X., & Preller, K. H. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0367-2 · Cited by 570
The role of serotonin 5-HT2A receptors in memory and cognition
Zhang, G., & Stackman, R. W. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00225 · Cited by 382
“…215 μg/kg; oral Spatial working memory task Humans ↔ Retrieval Carter et al., 2005 Psilocybin 0.1–1.5 mg/kg, i.p. Trace fear conditioning - mice ↑ Extinction Catlow et al., 2013 Psilocin 1.0 mg/kg, i.p. 4.0 mg/kg, i.p. MWM; Carousel maze (CM) Rats ↓Acquisition of CM; ↓Retrieval of MWM (4…”
BackgroundInfluentialSingewald, N., Schmuckermair, C., Whittle, N., Holmes, A., & Ressler, K. J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.004 · Cited by 390
“Psilocybin (5HT2A ag) (+) ns ns ip (Catlow et al. 2013)”
BackgroundInfluentialAdverse effects of psychedelics: From anecdotes and misinformation to systematic science
Schlag, A. K., Aday, J., Salam, I., Neill, J. C., & Nutt, D. J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069100 · Cited by 325
“…studies comparing ayahuasca users with matched controls have documented increased working memory and executive functioning in users (Bouso et al., 2012), supporting the idea that psychedelics have neuroplastic and neurogenic properties (Catlow et al., 2013; Jefsen et al., 2020; Ly et al., 2018).”
BackgroundDoss, M. K., Považan, M., Rosenberg, M. D., Sepeda, N. D., Davis, A. K., Finan, P. H., Smith, G. S., Pekar, J. J., Barker, P. B., Griffiths, R. R., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01706-y · Cited by 356
Kraehenmann, R., Preller, K. H., Scheidegger, M., Pokorny, T., Bosch, O. G., Seifritz, E., & Vollenweider, F. X. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.04.010 · Cited by 323
“(75) reported that psilocybin facilitated extinction of conditioned fear responses in the amygdala/hippocampus in mice, thus providing strong evidence of 5-HT1A/2Arelated inhibition of amygdala/hippocampus reactivity.”
BackgroundTowards an understanding of psychedelic-induced neuroplasticity
Calder, A. E., & Hasler, G. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01389-z · Cited by 313
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens
Halberstadt, A. L. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.016 · Cited by 312
“Psilocybin and TCB-2 have been shown to facilitate the extinction of fear conditioning in C57BL/6J mice (Catlow et al., 2013; Zhang et al., 2013), which could be a consequence of activating the projection from IL to the intercalated nuclei.”
Backgrounddos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316638008 · Cited by 306
LSD‐induced entropic brain activity predicts subsequent personality change
Lebedev, A. V., Kaelen, M., Lövdén, M., Nilsson, J., Feilding, A., Nutt, D. J., & Carhart‐Harris, R. L. (2016) · Human Brain Mapping · doi:10.1002/hbm.23234 · Cited by 303
“, 2013], extinction of conditioned fear in rodents [Catlow et al., 2013], and creativity [Frecska et al.”
BackgroundHalberstadt, A. L., Chatha, M., Klein, A. K., Wallach, J., & Brandt, S. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107933 · Cited by 278
“…plasticity and neurogenesis in rodents (Jones et al., 2009; Lima da Cruz et al., 2018; Ly et al., 2018) and produce positive effects in preclinical models relevant to anxiety, depression, and post-traumatic stress disorder (Catlow et al., 2013; Buchborn et al., 2014; Cameron et al. 2018, 2019).”
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Aleksandrova, L. R., & Phillips, A. G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.08.003 · Cited by 276
Long-term effects of psychedelic drugs: A systematic review
Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.03.017 · Cited by 257
de Vos, C. M. H., Mason, N. L., & Kuypers, K. P. C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.724606 · Cited by 269
Reviewing the Potential of Psychedelics for the Treatment of PTSD
Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa018 · Cited by 260
“Both psilocybin (Catlow et al., 2013) and DMT (Cameron et al.”
BackgroundTreatment of Posttraumatic Stress Disorder: A State-of-the-art Review
Burback, L., Brémault-Phillips, S., Nijdam, M. J., McFarlane, A., & Vermetten, E. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230428091433 · Cited by 208
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Classic hallucinogens in the treatment of addictions
Bogenschutz, M. P., & Johnson, M. W. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.03.002 · Cited by 226
“The effects of classic hallucinogens on adult neurogenesis have not been established, although a recent publication began to explore these effects (Catlow et al., 2013).”
Models of psychedelic drug action: modulation of cortical-subcortical circuits
Doss, M. K., Madden, M. B., Gaddis, A., Nebel, M. B., Griffiths, R. R., Mathur, B. N., & Barrett, F. S. (2022) · Brain · doi:10.1093/brain/awab406 · Cited by 199
Uthaug, M. V., van Oorsouw, K., Kuypers, K. P. C., van Boxtel, M., Broers, N. J., Mason, N. L., Toennes, S. W., Riba, J., & Ramaekers, J. G. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4988-3 · Cited by 212
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
Uthaug, M. V., Lancelotta, R., van Oorsouw, K., Kuypers, K. P. C., Mason, N., Rak, J., Šuláková, A., Jurok, R., Maryška, M., Kuchař, M., et al. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05236-w · Cited by 197
Brouwer, A., & Carhart-Harris, R. L. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959637 · Cited by 143
“Psychedelics have been shown to promote extinction-learning through 5-HT2AR agonism (Cameron et al., 2018; Catlow et al., 2013; Young et al., 2017) as well as low-level associative learning (Gimpl et al., 1979; Harvey, 1996, 2003; King et al., 1974; Morici et al., 2018; Romano et al., 2010; Welsh…”
BackgroundEffects of N,N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression
Cameron, L. P., Benson, C. J., Dunlap, L. E., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00134 · Cited by 171
Psychedelics and Other Psychoplastogens for Treating Mental Illness.
Vargas, M. V., Meyer, R., Avanes, A. A., Rus, M., & Olson, D. E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727117 · Cited by 166
Recreational drug use and human aggressive behavior: A comprehensive review since 2003
Tomlinson, M. F., Brown, M. F. D., & Hoaken, P. N. S. (2016) · Aggression and Violent Behavior · doi:10.1016/j.avb.2016.02.004 · Cited by 170
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
“…drug research have been established (Johnson et al., 2008) and studies have begun to produce some understanding of the neurochemical events directly responsible for producing hallucinogeninduced neuroplasticity (Catlow et al., 2013; Lepack et al., 2015), although many questions still remain.”
BackgroundBiochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity
Olson, D. E. (2022) · Biochemistry · doi:10.1021/acs.biochem.1c00812 · Cited by 129
3,4-Methylenedioxymethamphetamine facilitates fear extinction learning
Young, M. B., Andero, R., Ressler, K. J., & Howell, L. L. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.138 · Cited by 141
Low doses of LSD acutely increase BDNF blood plasma levels in healthy volunteers
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., Theunissen, E. L., Holze, F., Liechti, M. E., Varghese, N., Eckert, A., Feilding, A., Ramaekers, J. G., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00099 · Cited by 131
Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles
Baumeister, D., Barnes, G., Giaroli, G., & Tracy, D. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314527985 · Cited by 121
“Interestingly, Catlow and colleagues have investigated the effects of psilocybin, 25I-NBOMe (a synthetic phenethylamine) and ketanserin administrations on hippocampal neurogenesis and extinction of fear conditioning in adult rats [Catlow et al. 2013].”
BackgroundDark Classics in Chemical Neuroscience:N,N-Dimethyltryptamine (DMT)
Cameron, L. P., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00101 · Cited by 115
The learning of fear extinction
Furini, C., Myskiw, J., & Izquierdo, I. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.10.016 · Cited by 124
Classic Psychedelic Drugs: Update on Biological Mechanisms
Vollenweider, F. X., & Smallridge, J. W. (2022) · Pharmacopsychiatry · doi:10.1055/a-1721-2914 · Cited by 128
“In mice, low-dose psilocybin has been shown to facilitate the extinction of fear memory associated with a tendency to increase hippocampal neuroplasticity [104].”
Li, Y., Pan, K., Chen, L. V., Ning, J., Li, X., Yang, T., Terrando, N., Gu, J., & Tao, G. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0740-2 · Cited by 120
Psychedelic Microdosing: Prevalence and Subjective Effects
Cameron, L. P., Nazarian, A., & Olson, D. E. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1718250 · Cited by 110
“treating rodents with high acute doses of psychedelics (Cameron et al. 2018a; Catlow et al. 2013; Young et al. 2015), results that are consistent with the retrospective self-reports of psychedelic microdosing presented here.”
ResultYoung, M. B., Norrholm, S. D., Khoury, L. M., Jovanovic, T., Rauch, S. A. M., Reiff, C. M., Dunlop, B. W., Rothbaum, B. O., & Howell, L. L. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4684-8 · Cited by 108
“Conversely, the extinction of fear memory is consistently enhanced by 5-HT 2A receptor agonists (Catlow et al. 2013; Zhang et al. 2013), which also diminish the expression of FPS (Hughes et al. 2012).”
BackgroundDark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine
Dunlap, L. E., Andrews, A. M., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00155 · Cited by 106
Cecal Ligation and Puncture Results in Long-Term Central Nervous System Myeloid Inflammation
Singer, B. H., Newstead, M. W., Zeng, X., Cooke, C. L., Thompson, R. C., Singer, K., Ghantasala, R., Parent, J. M., Murphy, G. G., Iwashyna, T. J., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0149136 · Cited by 95
Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism
Bogenschutz, M. P., & Forcehimes, A. A. (2017) · Journal of Humanistic Psychology · doi:10.1177/0022167816673493 · Cited by 97
Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?
Kočárová, R., Horáček, J., & Carhart-Harris, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.661233 · Cited by 96
Psilocybin and MDMA for the treatment of trauma-related psychopathology
Bird, C. I. V., Modlin, N. L., & Rucker, J. J. H. (2021) · International Review of Psychiatry · doi:10.1080/09540261.2021.1919062 · Cited by 80
“Furthermore, animal studies have shown that psilocybin facilitates fear extinction in mice (Catlow et al., 2013) as well as promoting functional and structural neural plasticity in the PFC in vivo and in vitro (Ly et al., 2018).”
BackgroundDreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications
Kraehenmann, R. (2017) · Current Neuropharmacology · doi:10.2174/1573413713666170619092629 · Cited by 92
“Moreover, there is accumulating evidence from animal studies [103-105] indicating that psychedelics may facilitate extinction of conditioned fear memory by enhancing BDNF-dependent neuroplasticity.”
BackgroundInserra, A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00330 · Cited by 91
“…animals present decreased freezing behaviour in those paradigms, this might suggest that indeed Ayahuasca is beneficial in the extinction of fear conditioning, as it was previously demonstrated with 3,4-methylenedioxymethamphetamine and low-dose psilocybin (Catlow et al., 2013; Young et al., 2015).”
BackgroundInfluentialThe Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Antonio, J. H., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C. F., et al. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666231027111147 · Cited by 104
Serotonin 2A receptors are a stress response system: implications for post-traumatic stress disorder
Murnane, K. S. (2019) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000459 · Cited by 99
“Facilitated extinction of fear conditioning has also been reported with other 5-HT2A receptor agonists as psilocybin facilitates extinction of fear conditioning at low doses that tended to increase neurogenesis in the hippocampus (Catlow et al., 2013).”
BackgroundPsilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity
Du, Y., Li, Y., Zhao, X., Yao, Y., Wang, B., Zhang, L., & Wang, G. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002647 · Cited by 94
“[21] However, the neuroprotective mechanism of psilocybin in treating PTSD remains unclear.”
BackgroundMethodResultInfluentialDakwar, E., Nunes, E. V., Hart, C. L., Hu, M. C., Foltin, R. W., & Levin, F. R. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.005 · Cited by 85
Psychedelic perceptions: mental health service user attitudes to psilocybin therapy
Corrigan, K., Haran, M., McCandliss, C., McManus, R., Cleary, S., Trant, R., Kelly, Y., Ledden, K., Rush, G., O’Keane, V., et al. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02668-2 · Cited by 84
Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy
Dodd, S., Norman, T. R., Eyre, H. A., Stahl, S. M., Phillips, A., Carvalho, A. F., & Berk, M. (2023) · CNS Spectrums · doi:10.1017/s1092852922000888 · Cited by 73
“Furthermore, the increase in neurogenesis was accompanied by extinction of conditioned fear related behaviors.(45) A complex interplay between serotonergic and glutamatergic systems in the prefrontal circuits may underlie the potential therapeutic effects of psilocin in depressive and anxiety states.”
Raut, S. B., Marathe, P. A., van Eijk, L., Eri, R. D., Ravindran, M., Benedek, D. M., Ursano, R. J., Canales, J. J., & Johnson, L. R. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108195 · Cited by 84
Psychedelic‐inspired approaches for treating neurodegenerative disorders
Saeger, H. N., & Olson, D. E. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15544 · Cited by 74
“Psilocybin has been shown to promote fear extinction in mice (Catlow et al., 2013), and produce long- lasting antidepressant- like effects in rats subjected to the forced swim test (Hibicke et al., 2020).”
BackgroundTherapeutic mechanisms of psychedelics and entactogens
Heifets, B. D., & Olson, D. E. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01666-5 · Cited by 79
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
“A study in mice injected with low doses of psilocybin resulted in extinguished cued fear conditioning significantly more rapidly than high-dose psilocybin or saline-treated mice (125).”
BackgroundPsychedelics as a Treatment for Alzheimer’s Disease Dementia
Jones, S. V., & O’Kelly, A. (2020) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2020.00034 · Cited by 71
“In a mouse model of fear conditioning, both low and high dose psilocybin led to complete resolution of a cued fear response in animals that had been primed for a shock by an auditory tone (Catlow et al., 2013).”
BackgroundInfluentialMertens, L. J., & Preller, K. H. (2021) · Pharmacopsychiatry · doi:10.1055/a-1341-1907 · Cited by 65
“The authors also found dose-dependent decreases in hippocampal neurogenesis, although for the low psilocybin dose, a trend toward increased neurogenesis was evident [112].”
BackgroundSmausz, R., Neill, J. C., & Gigg, J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221092508 · Cited by 70
“Indeed, low doses (0.1 and 0.5 mg/ kg) of psilocybin promoted neurogenesis in mouse HC (Catlow et al., 2013).”
BackgroundInfluentialSingewald, N., Sartori, S. B., Reif, A., & Holmes, A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109418 · Cited by 67
Zhao, X., Du, Y., Yao, Y., Dai, W., Yin, Y., Wang, G., Li, Y., & Zhang, L. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241249436 · Cited by 71
“Several rare basic studies assessed the antidepressant behavioural effects of psilocybin 24 h post-administration which suggested its positive impact (Cameron et al., 2023; Catlow et al., 2013; Hesselgrave et al., 2021; Hibicke et al., 2020; Shao et al., 2021).”
BackgroundMushroom Toxins: Chemistry and Toxicology
Yin, X., Yang, A.-A., & Gao, J. (2019) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b00414 · Cited by 65
Psilocybin lacks antidepressant-like effect in the Flinders Sensitive Line rat
Jefsen, O., Højgaard, K., Christiansen, S. L., Elfving, B., Nutt, D. J., Wegener, G., & Müller, H. K. (2019) · Acta Neuropsychiatrica · doi:10.1017/neu.2019.15 · Cited by 63
“Other studies have investigated the therapeutic potential of psilocin or psilocybin in animal models of other psychiatric disorders such as anxiety (Horsley et al., 2018), OCD (Sard et al., 2005), and PTSD (Catlow et al., 2013).”
BackgroundVarker, T., Watson, L., Gibson, K., Forbes, D., & O'Donnell, M. L. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1817639 · Cited by 74
“Psilocybin has been found to reduce amygdala reactivity during emotion processing (Kraehenmann et al. 2014), and in animal studies, to facilitate the extinction of a fear response and increase hippocampal neurogenesis (Catlow et al. 2013).”
BackgroundPotential Differences in Psychedelic Actions Based on Biological Sex
Shadani, S., Conn, K., Andrews, Z. B., & Foldi, C. J. (2024) · Endocrinology · doi:10.1210/endocr/bqae083 · Cited by 66
“Moreover, psilocybin promotes the rapid extinction of the conditioned fear response in male mice (87, 88) and may be important for posttraumatic stress disorder, at least in males.”
BackgroundAgnorelli, C., Spriggs, M. J., Godfrey, K., Sawicka, G., Bohl, B., Douglass, H. M., Fagiolini, A. M., Hashemi, P., Carhart-Harris, R. L., Nutt, D. J., et al. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106132 · Cited by 68
“Also, lower doses facilitated the extinction of conditioned fear response, while the higher dose did not affect this behavioral output (Catlow et al., 2013).”
Ona, G., & Bouso, J. C. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.09.035 · Cited by 58
Transient Elevation of Plasma Glucocorticoids Supports Psilocybin-Induced Anxiolysis in Mice
Jones, N., Zahid, Z., Grady, S. M., Sultan, Z. W., Zheng, Z., Razidlo, J. A., Banks, M. I., & Wenthur, C. J. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00123 · Cited by 61
Psilocybin for Trauma-Related Disorders
Khan, A. J., Bradley, E., O’Donovan, A., & Woolley, J. (2022) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2022_366 · Cited by 67
Exploring DMT: Endogenous role and therapeutic potential
Schimmelpfennig, J., & Jankowiak-Siuda, K. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110314 · Cited by 58
Lysergic acid diethylamide: a drug of ‘use’?
Das, S., Barnwal, P., Ramasamy, A., Sen, S., & Mondal, S. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316640440 · Cited by 60
“The effects of classic hallucinogens on adult neurogenesis have not been established, although a recent study tried to explore these effects [Catlow et al. 2013].”
Zhu, L., Li, L., Li, X.-Z., & Wang, L. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.738211 · Cited by 51
Foldi, C. J., Liknaitzky, P., Williams, M., & Oldfield, B. J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00043 · Cited by 51
Schindler, E. A. D., Wallace, R. M., Sloshower, J. A., & D’Souza, D. C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00177 · Cited by 47
“In mice, a single low dose injection of psilocybin (0.1 mg/kg i.p.) tended to stimulate hippocampal neurogenesis 2 weeks after injection, though a high dose (1.0 mg/kg i.p.) inhibited it (Catlow et al., 2013).”
BackgroundInfluentialMagaraggia, I., Kuiperes, Z., & Schreiber, R. (2021) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2021.107467 · Cited by 49
“Other studies in rodents reported an association between the neuroplastic effects of psychedelics and increased performance in fear extinction and learning and memory tasks (Morales-Garcia et al., 2020; Cameron et al., 2018; Catlow et al., 2013; Buchborn et al., 2014).”
BackgroundInfluentialPędzich, B. D., Rubens, S., Sekssaoui, M., Pierre, A., Schuerbeek, A. V., Marin, P., Bockaert, J., Valjent, E., Bécamel, C., & Bundel, D. D. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01324-2 · Cited by 56
“In preclinical studies, the psychedelics psilocybin and TCB-2 enhanced the acquisition of trace fear extinction in mice [34, 35].”
BackgroundResultHusain, M. I., Ledwos, N., Fellows, E., Baer, J., Rosenblat, J. D., Blumberger, D. M., Mulsant, B. H., & Castle, D. J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1076459 · Cited by 50
“5-methoxy(MeO)-DMT (42) and psilocybin (43) increase neurogenesis in rats and the study involving psilocybin suggested this might be dose-dependent (43).”
BackgroundWolf, G., Singh, S., Blakolmer, K., Lerer, L. B., Lifschytz, T., Heresco‐Levy, U., Lotan, A., & Lerer, B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01832-z · Cited by 52
“0 mg/kg) significantly decreasing neurogenesis [92].”
BackgroundPsilocin acutely alters sleep-wake architecture and cortical brain activity in laboratory mice
Thomas, C. W., Blanco‐Duque, C., Bréant, B. J. B., Goodwin, G. M., Sharp, T., Bannerman, D. M., & Vyazovskiy, V. V. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01846-9 · Cited by 53
The role of neurotrophic factors in novel, rapid psychiatric treatments
Kim, J., He, M. J., Widmann, A. K., & Lee, F. S. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01717-x · Cited by 51
Psilocybin Facilitates Fear Extinction: Importance of Dose, Context, and Serotonin Receptors
Woodburn, S. C., Levitt, C. M., Koester, A., & Kwan, A. C. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00279 · Cited by 58
Psychedelics and virtual reality: parallels and applications
Aday, J. S., Davoli, C. C., & Bloesch, E. K. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320948356 · Cited by 47
“…MAO, monoamine oxidase inhibitor; OCD, obsessive-compulsive disorder. emotional breakthrough, 43 ego dissolution, 44 neuroplasticity, 45 neurogenesis, 13,24,46 and decreases in default mode network (DMN) activity have each been theorized to underlie the therapeutic benefits linked to psychedelics.”
BackgroundInserra, A., Campanale, A., Cheishvili, D., Dymov, S., Wong, A. H. Y., Marçal, N., Syme, R. A., Taylor, L., Gregorio, D. D., Kennedy, T. E., et al. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110594 · Cited by 47
Catalysts for change: the cellular neurobiology of psychedelics
Banks, M. I., Zahid, Z., Jones, N. T., Sultan, Z. W., & Wenthur, C. J. (2021) · Molecular Biology of the Cell · doi:10.1091/mbc.e20-05-0340 · Cited by 37
“For example, psychedelics enhance both the acquisition and extinction of fear conditioning in rodents (Catlow et al., 2013; Zhang et al., 2013).”
BackgroundPsychedelics for Brain Injury: A Mini-Review
Khan, M., Carter, G. T., Aggarwal, S. K., & Holland, J. A. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.685085 · Cited by 43
“Acute administration of psilocybin to mice alters hippocampal neurogenesis in a non-linear fashion (35).”
BackgroundPsychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential
Allen, J., Dames, S., Foldi, C. J., & Shultz, S. R. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02360-0 · Cited by 47
The fibrinolytic system: A new target for treatment of depression with psychedelics
Idell, R. D., Florova, G., Komissarov, A. A., Shetty, S., Girard, R., & Idell, S. (2017) · Medical Hypotheses · doi:10.1016/j.mehy.2017.01.013 · Cited by 41
“In mice, low dose psilocybin has been demonstrated to rapidly extinguish cued fear conditioning and induce a slight non-significant trend toward increased hippocampal neurogenesis, suggesting a potential role in the treatment of Post-Traumatic Stress Disorder (PTSD) [84] and possibly depression.”
BackgroundEleftheriou, M. E., & Thomas, E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.707057 · Cited by 39
“Neurogenesis may also contribute to these effects, as psilocybin, ketamine as well as β-carbolines present in the ayahuasca brew, have all been shown to enhance neurogenesis in animal studies (42, 67, 68).”
BackgroundThe Effects of Psychedelics on Neuronal Physiology
Hatzipantelis, C. J., & Olson, D. E. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-042022-020923 · Cited by 44
“Conversely, acute administration of DOI and LSD had no effect on hippocampal neurogenesis (110), while psilocybin and 25I-NBOMe decreased hippocampal neurogenesis (111).”
The Effects of Daytime Psilocybin Administration on Sleep: Implications for Antidepressant Action
Dudysová, D., Janků, K., Šmotek, M., Saifutdinová, E., Kopřivová, J., Bušková, J., Mander, B. A., Brunovský, M., Zach, P., Korčák, J., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.602590 · Cited by 41
“Overall, there has been an increasing preclinical (Catlow et al., 2013; Baumeister et al., 2014) and clinical (Carhart-Harris et al.”
BackgroundPsychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action
Rieser, N. M., Herdener, M., & Preller, K. H. (2021) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2021_284 · Cited by 37
Role of Psychedelics in Treatment-Resistant Depression
Kamal, S., Jha, M. K., & Radhakrishnan, R. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.004 · Cited by 38
The renaissance in psychedelic research: What do preclinical models have to offer
Murnane, K. S. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.08.003 · Cited by 39
Psychedelic medicine: The biology underlying the persisting psychedelic effects
Kuypers, K. P. C. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.02.029 · Cited by 35
Hippocampal volume, function, and related molecular activity in anorexia nervosa: A scoping review
Keeler, J. L., Patsalos, O., Thuret, S., Ehrlich, S., Tchanturia, K., Himmerich, H., & Treasure, J. L. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1850256 · Cited by 37
Borbély, E., Varga, V. É., Szögi, T., Schuster, I., Bozsó, Z., Penke, B., & Fülöp, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052514 · Cited by 39
“Similar to this finding, another tryptamine, psilocybin (4-phosphoryloxy-N, N-dimethyltryptamine) with a chemical structure close to that of DMT and a high binding affinity to 5-HT2A receptors (Kd = 6 nM), was also found to impair synaptic growth and neurogenesis (proliferation and neuronal survival) [109].”
ResultHansen, M., Jacobsen, S. E., Plunkett, S., Liebscher, G., McCorvy, J. D., Bräuner‐Osborne, H., & Kristensen, J. L. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.12.011 · Cited by 35
Kajta, M., Wnuk, A., Rzemieniec, J., Litwa, E., Lasoń, W., Zelek-Molik, A., Nalepa, I., Rogóż, Z., Grochowalski, A. R., & Wójtowicz, A. K. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2017.03.001 · Cited by 35
“Changes in the levels of serotonin and its receptors can affect the development of specific brain areas, including the cortex and hippocampus [45,46], and influence behavior as we observed in p,p’-DDT-treated animals.”
Metadata
- Authors
- Catlow, B. J., Song, S., Paredes, D. A., Kirstein, C. L., & Sanchez-Ramos, J.
- Affiliations
- Lieber Institute for Brain Development (US)
- University of South Florida (US)
- Venue
- Experimental Brain Research
- Published
- 2013-06-02
- Volume
- 228
- Issue
- 4
- Pages
- 481-491
- ISSN
- 0014-4819 (ISSN-L)
- 1432-1106
- OpenAlex
- W2051271111
- Semantic Scholar
- f85018b1b5d6ec225219bde72260340ba25be97a
- Cited by
- 266
- References
- 70
- Citations by year
- 2026: 15 · 2025: 21 · 2024: 45 · 2023: 40 · 2022: 30 · 2021: 29 · 2020: 28 · 2019: 12 · 2018: 11 · 2017: 7 · 2016: 16 · 2015: 4 · 2014: 6 · 2013: 1
- FWCI
- 10.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Experimental Brain Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Memory and Neural Mechanisms
- Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
- Keywords
- psilocybin, hippocampal neurogenesis, trace fear conditioning, fear extinction, 5-HT2A receptor agonists, ketanserin, serotonin, dentate gyrus, BrdU labeling, post-traumatic stress disorder, amygdala
- MeSH terms
- Animals, Conditioning, Psychological, Extinction, Psychological, Fear, Hallucinogens, Hippocampus, Male, Mice, Inbred C57BL, Psilocybin, Mice, Neurogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.